Benefit‐risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers

Nivolumab 3 mg/kg every 2 weeks (Q2W) has been approved in Japan for various cancers; however, use of a flat dose is expected to simplify dosing and administration. A quantitative clinical pharmacology approach was used to assess the benefit‐risk profile of nivolumab 240 mg Q2W relative to the appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Bei, Di, Osawa, Mayu, Uemura, Shinji, Ohno, Tomoya, Gobburu, Jogarao, Roy, Amit, Hasegawa, Mayumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004547/
https://www.ncbi.nlm.nih.gov/pubmed/31773815
http://dx.doi.org/10.1111/cas.14252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004547/
https://www.ncbi.nlm.nih.gov/pubmed/31773815
http://dx.doi.org/10.1111/cas.14252

Ejemplares similares